CERo Therapeutics (NASDAQ:CERO) Raised to Strong-Buy at D Boral Capital
D Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO – Free Report) to a strong-buy rating in a research note published on Tuesday,Zacks.com reports. Separately, D. Boral Capital began coverage on shares of CERo Therapeutics in a research report on Tuesday. They set a “buy” rating and a $11.00 target price for the company. Read […]
D Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO – Free Report) to a strong-buy rating in a research note published on Tuesday,Zacks.com reports. Separately, D. Boral Capital began coverage on shares of CERo Therapeutics in a research report on Tuesday. They set a “buy” rating and a $11.00 target price for the company. Read […]